

POSTER BOARD NO.	ABSTRACT	TITLE	Presenter/Author	
1	ARNI0019	Systematic Literature Review of the Signs and Symptoms of Respiratory Syncytial Virus in Young Children	Jessica	Costello
2	ARNI0023	Systematic Literature Review of the Signs and Symptoms of Respiratory Syncytial Virus in High-Risk Adults and Immunocompromised Populations	Jessica	Costello
3	ARNI0140	Development of a Mucosal Virus Vected Vaccine for Bovine Parainfluenza Virus Type 3	Courtney	Hawthorn
4	ARNI0233	Coinfection of RSV with SARS-CoV-2 results in altered RSV infection kinetics and diminished innate immune responses	Erin	Getty
5	ARNI0186	Airway epithelial cell gene expression following respiratory syncytial virus infection shows differential chronological and gestational age-related responses in early life.	Mary	McCabe
6	ARNI0002	A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein	Jarrod	Mousa
7	ARNI0052	RSV burden in the Middle Eastern countries among adults and elderly populations Systematic Review and Meta Analysis	Eiman	Gaid
8	ARNI0030	Burden of Respiratory Syncytial Virus (RSV) in Adults in the United Kingdom (UK): A Systematic Literature Review (SLR) and Gap Analysis	Annie	Lied-Lied
9	ARNI0053	Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine	Galit	Alter
10	ARNI0166	Acute and Long-Term Costs among US Infants with Respiratory Syncytial Virus in the First Year of Life	Kimberly	Shea
11	ARNI0113	Validation of a Global Respiratory Severity Score in Infants with Primary Respiratory Syncytial Virus (RSV) Infection	Mary	Caserta
12	ARNI0078	In vitro and in vivo evaluation of a novel bivalent HMPV/RSV live-attenuated vaccine candidate	Julia	Dubois
13	ARNI0111	Burden of respiratory syncytial virus-associated acute respiratory illness and severe acute respiratory illness South African Children	Jocelyn	Moyes
14	ARNI0112	The economic burden of RSV-associated illness in children aged	Jocelyn	Moyes
15	ARNI0237	Estimation of the timing and intensity of the RSV season preceding and during the COVID-19 pandemic in South Africa 2010-2021	Sibongile	Walaza
16	ARNI0037	Epidemiology of respiratory syncytial virus in children aged less than 5 years during the COVID-19 pandemic in South Africa	Nicole	Wolter
17	ARNI0123	Impact of Respiratory Syncytial Virus infection in infants on the quality of life of affected families	Christina	Tischer
18	ARNI0131	A Multisite Initiative to Assess Transplacental Transfer of Naturally-Acquired RSV Maternal Antibodies in Preterm and Full Term Infants	Jessica	Atwell
19	ARNI0098	Epidemiology of RSV-associated hospitalizations in U.S. children aged <5 years before and during the COVID-19 pandemic, RSV-NET October 2018-2022	Fiona	Havers
20	ARNI0138	A live attenuated codon-pair-deoptimized human respiratory syncytial virus (RSV) vaccine candidate genetically stabilized in vitro is immunogenic and protective in hamsters	Cyril	Le Nouen
21	ARNI0210	RSV vaccine acceptability among pregnant and lactating individuals in the wake of the COVID-19 vaccine experience	Alisa	Kachikis

POSTER BOARD NO.	ABSTRACT	TITLE	Presenter/Author	
22	ARNI0116	Seasonality of Respiratory Syncytial Virus and Pediatric RSV-Associated Hospitalizations in the United States, 2017-2020	Mila	Prill
23	ARNI0157	Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV Seronegative Children	Ursula	Buchholz
24	ARNI0128	Genomic characterisation of respiratory syncytial virus (RSV) causing disease in South Africa, 2021 - 2022	Daniel Gyamfi	Amoako
25	ARNI0047	Lack of Temporal Prevalence and Geographic Distribution of Nirsevimab Escape Variants among Global RSV Strains Since 1956	Michael	Abram
26	ARNI0085	NIRSEVIMAB AFFORDS HIGH LEVELS OF RESPIRATORY SYNCYTIAL VIRUS NEUTRALISING ANTIBODIES FOLLOWING A SINGLE DOSE	Deidre	Wilkins
27	ARNI0086	POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE OF NIRSEVIMAB FOR THE PREVENTION OF RSV DISEASE IN INFANTS: EXTRAPOLATION OF EFFICACY TO INFANTS WITH HEART OR LUNG DISEASE OR PREMATUREITY	Ulrika	Wählby Hamren
28	ARNI0114	RSV Pathogen Mutations: An Open Source Browser to Visualize and Track RSV F Protein Variants	David	Tabor
29	ARNI0083	Exploring the burden of respiratory syncytial virus infections among adults in Denmark.	Amanda Marie	Cavling Clausen
30	ARNI0044	IN VIVO EFFICACY OF EDP-323, A NOVEL L-PROTEIN INHIBITOR, FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS	Rachel	Levene
31	ARNI0194	Respiratory Syncytial Virus Sequelae among Adults in High Income Countries: A Systematic Literature Review	Elizabeth	Begier
32	ARNI0177	Unraveling specific mechanisms of community deaths due to RSV in Buenos Aires, Argentina	Paola	De la Iglesia Niveyro
33	ARNI0184	Role of RSV infection and factors associated with apnea during acute respiratory tract infections	Julia	Dvorkin
34	ARNI0051	A respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine elicits persistent immune responses when administered to older adults in a phase 1/2 randomized trial	Veronica	Hulstrøm
35	ARNI0274	Respiratory Syncytial Virus Knowledge, Attitudes, and Perceptions Among Older Adults in the United States	Elizabeth	La
37	ARNI0154	RSVpreF subunit vaccine antibody response modeled through two RSV seasons in older adults	Kena	Swanson
38	ARNI0110	Mathematical modelling of RSV transmission and estimating the impact of novel pharmaceutical approaches in Tokyo, Japan	Ayaka	Monoï
39	ARNI0038	Disease burden of RSV infections in young children in primary care: preliminary results from the RSV ComNet study in five European countries	Jojanneke	Van Summeren
40	ARNI0040	Societal impact of RSV infections in young children in primary care in Italy	Jojanneke	Van Summeren
41	ARNI0039	Defining the Burden of Disease Pyramid of RSV in the European Union: estimates of RSV-associated hospitalizations in children under 5 years of age	Marco	Del Riccio
42	ARNI0125	Cost-effectiveness of monoclonal antibody and maternal immunization against Respiratory Syncytial Virus (RSV) in Danish children younger than 5 years	Xiao	Li
43	ARNI0042	Defining the burden of disease pyramid of RSV in the European Union: estimates of RSV-associated hospitalisations in adults	Richard	Osei-Yeboah

POSTER BOARD NO.	ABSTRACT	TITLE	Presenter/Author	
44	ARNI0249	Incidence of respiratory syncytial virus (RSV)-associated hospitalization among American Indian and Alaska Native children	Laura	Hammitt
46	ARNI0258	Genetic Diversity of Respiratory Syncytial Virus and its Influence on Clinical Outcome in Adult Populations	Estefany	Rios Guzman
47	ARNI0146	Development and validation of a simplified severity score for RSV bronchiolitis	Zakariya	Sheikh
48	ARNI0205	Protective efficacy of an inactivated whole virus RSV vaccine in mice	Valentina	Eberlein
49	ARNI0095	Epithelial composition of human nasal organoids after infection with RSV	Gina	Aloisio
50	ARNI0170	Microparticle Vaccines Presenting the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Eosinophil Infiltration in Lungs Post-challenge	Thomas J.	Powell
52	ARNI0101	GENOMICS ANALYSIS OF RSV IN ARGENTINA BETWEEN 2018-2021	Dolores	Acuña
55	ARNI0046	RSV SEVERITY BEFORE AND AFTER THE FIRST WAVES OF THE SARS CoV 2 PANDEMIC: A COHORT STUDY IN MELGHAT INDIA	Rowena	Crow
56	ARNI0191	The cost of care for children hospitalized with respiratory syncytial virus (RSV) associated lower respiratory tract infection (LRTI) in Kenya	Joyce	Nyiro
58	ARNI0067	Relative Contribution of Diagnostic Testing to RSV Diagnosis in Adults in United States	Evan	Anderson
59	ARNI0068	Burden of Respiratory Syncytial Virus and Influenza Among Adults 50 Years of Age or Greater Hospitalized with Acute Respiratory Infection vs Healthy Controls in the Pre-SARS-CoV-2 Era in the United States	Evan	Anderson
60	ARNI0223	RSV Hospitalization Rates in Colorado: Changing Epidemiology 2006-2019	Robert	Suss
61	ARNI0213	RSV Health Care Resource Utilization (HCRU) in Children's Hospitals Across The United States Before and After the COVID-19 Pandemic, 2015-2022	Robert	Suss
62	ARNI0176	Lab adapted vs contemporary RSVs: single amino acid changes modulate F protein mediated cell fusion	Martin	Ludlow
70	ARNI0175	Human Metapneumovirus Fusion Protein Immunogens in Nanoparticle Format	Baoshan	Zhang
71	ARNI0134	MOLECULAR EPIDEMIOLOGY OF RSV IN ARGENTINA, 2017-2021	Mara	Russo
72	ARNI0236	Novel paramyxovirus vectored vaccines induce high neutralising antibody titres and specific T cell responses against bovine Respiratory Syncytial virus	Olivier	Touzelet
73	ARNI0142	Respiratory syncytial virus provides protection against a subsequent influenza A virus infection	Stacey	Hartwig
74	ARNI0141	Activation of the cGAS-STING pathway following RSV Line 19 infection	Ann	Miller
76	ARNI0069	Evaluation of a Human 3D Airway Tissue Culture Model for the Study of Respiratory Syncytial Virus infection and the Development of Antiviral Drugs	Nicole	McAllister
77	ARNI0064	AN IMPROVED TOOLKIT FOR IN VITRO HMPV CHARACTERIZATION	Joyce	Sweeney

POSTER BOARD NO.	ABSTRACT	TITLE	Presenter/Author	
78	ARNI0062	RISK FACTORS FOR THE DEVELOPMENT OF SEVERE OR VERY SEVERE RSV LRTI IN INDIAN INFANTS: A COHORT STUDY IN MELGHAT INDIA	Rowena	Crow
79	ARNI0246	Survival and long-lived functional enhancement of murine alveolar macrophages targeted early following RSV infection	Kody	Waldstein
80	ARNI0250	Whole genome sequencing of RSV on ONT platform	Kseniya	Komissarova
81	ARNI0209	Incidence of respiratory syncytial virus in older adults: Limitations of current data	Samantha	Kurosky
83	ARNI0121	Burden and management of RSV in a pediatric primary care center during the second Covid-19 winter season	Julian	Voitl
86	ARNI0260	Protection against endemic respiratory virus co-infection using an antibody cocktail	Maddi	Bibby
88	ARNI0195	Saliva as an alternative to nasopharyngeal swabs for detection of respiratory syncytial virus (RSV) in children	Annefleure	Langedijk
90	ARNI0240	The effect of case fatality estimates on RSV prevention cost-effectiveness	Meagan	Fitzpatrick
91	ARNI0151	Optimizing next-generation RSV prevention in Mali: a cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis	Meagan	Fitzpatrick
92	ARNI0100	LOW LEVELS OF RSV TESTING AMONG ADULTS HOSPITALIZED FOR LOWER RESPIRATORY TRACT INFECTION IN THE UNITES STATES: IMPLICATIONS FOR THE ACCURACY OF INCIDENCE STUDIES	Samantha	Kurosky
93	ARNI0247	Systematic Literature Review: Under-ascertainment of Respiratory Syncytial Virus infection in adults due to diagnostic testing limitations	Elizabeth	Begier
94	ARNI0252	Epidemiologic Modeling to Inform RSV Trial Operations during the COVID-19 Pandemic	Eileen	Farnon
95	ARNI0164	The RSV attachment protein affects dendritic cell maturation	Anke	Lakerveld
96	ARNI0207	Clinical course of outpatient RSV disease in healthy term-born European infants - a prospective birth cohort study (RESCEU)	Sarah	Hak
97	ARNI0109	GP consultations before hospital admission for RSV respiratory tract infections in children	Marie	Billard
98	ARNI0124	Respiratory syncytial virus related complications on pediatric intensive care units (BRICK study)	Emily	Phijffer
99	ARNI0013	Evaluation of the respiratory syncytial virus G-directed neutralizing antibody response in the human airway epithelial cell model	Michael	Kishko
100	ARNI0035	Optimization and characterization of a live attenuated respiratory syncytial virus vaccine candidate	Judith	Alamares-Sapuyay
101	ARNI0193	Potential impact of maternal vaccination on respiratory syncytial virus-related childhood mortality in low-income and middle-income countries: a modelling study	Joukje	Willemsen
103	ARNI0197	One-step multiplex RT-PCR amplicon-based next generation sequencing of human respiratory syncytial virus subgroups A and B genomes	Yi-Mo	Deng
104	ARNI0259	RSV vaccines/prophylactics: key learnings from the RSV challenge model and Efficacy of Vaccines	Alex	Mann

POSTER BOARD NO.	ABSTRACT	TITLE	Presenter/Author	
105	ARNI0060	Respiratory syncytial virus burden in infants born before or during the season in England in their first year of life	Craig	Davidson
106	ARNI0016	New perspectives on respiratory syncytial virus (RSV) surveillance at the national level; lessons from the COVID-19 pandemic	Anne	Teirlinck
107	ARNI0106	Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study	Lien Anh Ha	Do
108	ARNI0105	Respiratory syncytial virus (RSV) and influenza infections in children under 2 years of age in Ulaanbaatar, Mongolia	Lien Anh Ha	Do
109	ARNI0199	Removal of the N-glycans in p27 of the respiratory syncytial virus fusion protein	Lotte	Jacobs
110	ARNI0200	Risk Factors Associated with Severe RSV Infection in Infants: what is the Role of Viral Co-infections?	Kim	Stobbelaar
111	ARNI0050	Interleukin-1a evokes cachexia post respiratory viral infection	Ziyin	Wang
112	ARNI0226	Inhibition of the TLR4 signalling pathway with TAK-242 reduces RSV infection and cytokine release in primary airway epithelial cells	Lindsay	Broadbent
113	ARNI0026	A Heligmosomoides polygyrus induced serum-borne factor promotes monocytosis and protects against respiratory syncytial virus infection in the lung	Matthew	Burgess
114	ARNI0036	Preterm Infants Exhibit a Reduced Pro-inflammatory Immune Response to RSV	Jeremy	Anderson
115	ARNI0222	Structure-based Design of Human Metapneumovirus Fusion Protein Yields Improved Neutralizing Antibody Responses	Tongqing	Zhou
116	ARNI0182	Immune and inflammatory markers associated with RSV disease in experimentally infected older adults	Stephanie	Ascough
117	ARNI0212	Transcriptomic changes in blood and bronchus associated with RSV disease in experimentally infected adults	Pete	Dayananda
118	ARNI0227	Systematic Literature Review of Risk Factors for Poor Outcomes among Adults with RSV Infection	Elizabeth	Begier
119	ARNI0094	Perturbations in Respiratory Syncytial Virus (RSV) Activity During the SARS-CoV-2 Pandemic	Ann R.	Falsey
120	ARNI0073	New insights on RSV nucleoprotein structure and RNA encapsidation mechanism	Marie	Galloux
121	ARNI0165	Full genome sequencing reveals circulation of 6 HMPV lineages since 2005, with recent predominance of viruses with duplications in the G gene	Bernadette	Van den Hoogen
122	ARNI0162	Transcriptional and metabolic dynamics of primary human lung cells acutely infected by RSV	Thomas	Pietschmann
123	ARNI0071	Improving virus neutralization assays for human respiratory syncytial virus using airway organoids	Laurine	Rijsbergen
124	ARNI0074	Bacterial and viral interference affects the susceptibility of respiratory epithelial cells to human respiratory syncytial virus	Laura L.A.	van Dijk
125	ARNI0144	Vaccination with RSV prefusion-stabilized F protein elicits neutralizing site VI antibodies	Ryan	McCool

POSTER BOARD NO.	ABSTRACT	TITLE	Presenter/Author	
126	ARNI0126	Characteristics of the unusual inter-seasonal RSV circulation during COVID-19 pandemic, 2021, Germany	Janine	Reiche
127	ARNI0007	Resource-effective whole genome sequencing of RSV using hybridization capture	Janine	Reiche
128	ARNI0017	Annual RSV-associated hospitalization rates among children aged less than 5 years during 2021 and comparison to pre-pandemic rates, New Vaccine Surveillance Network (NVSN)	Meredith	McMorrow
129	ARNI0104	Hospitalizations Associated with Respiratory Syncytial Virus Among U.S. Children Less Than 5 Years of Age, New Vaccine Surveillance Network (NVSN), December 2016 - September 2020	Aaron	Curns
130	ARNI0115	The multifunctional role of RSV inclusion bodies; from viral RNA replication to the rerouting of innate immune signalling	Fatoumatta	Jobe
131	ARNI0229	B cell-dependent protection during acute pneumovirus infection in immunodeficient mice	Christine	Kreml
132	ARNI0208	Efficacy of PreF subunit BRSV vaccine in calves: towards a translational model for infant vaccination.	Sabine	Riffault
133	ARNI0088	RSV and Influenza surveillance in school children and adolescents during 2 months of the second semester of 2021.	Maria Florencia	Lucion
136	ARNI0264	Quantification of Clesrovimab (MK-1654), an Investigational, Half-life Extended, Anti-Respiratory Syncytial Virus Protein F Human Monoclonal Antibody in the Nasal Compartment of Healthy Adults	Kalpiti	Vora
137	ARNI0054	Clinical trial simulation predicts higher efficacy against RSV for MK-1654 than for maternal vaccination	Brian	Maas
138	ARNI0008	Gap analyses to assess Canadian readiness for respiratory syncytial virus vaccines	April	Killikelly
139	ARNI0148	Constitutive differences in adult and infant neutrophil transepithelial migration during in vitro modelling of RSV infection of primary differentiated airway epithelial cells	Elisabeth	Robinson
140	ARNI0063	Isolation of wild-type BRSV in differentiated bovine tracheobronchial epithelial cells cultured at air-liquid interface	Rik	de Swart
141	ARNI0089	Out-of-season epidemic of respiratory syncytial virus, starting summer 2021, Denmark	Ramona	Trebbien
142	ARNI0025	Experimental and natural infection in calves with bovine respiratory disease associated viruses.	Louise	Cosby
143	ARNI0076	Bovine Respiratory Syncytial Virus experimental challenge study: Whole blood transcriptome response in dairy calves	Stephanie	O Donoghue
144	ARNI0231	Integrated surveillance: monitoring coinfections of influenza, SARS-CoV-2, RSV and other respiratory viruses	Siddhivinayak	Hirve
145	ARNI0241	RSV surveillance in the context of the COVID-19 pandemic: lessons learnt and opportunities offered	Mandeep	Chadha
146	ARNI0006	Transmission of respiratory syncytial virus (RSV) from symptomatic and asymptomatic individuals in an urban and a rural community in South Africa, 2017-2018: results of the PHIRST cohort study	Cheryl	Cohen
147	ARNI0032	COST-EFFECTIVENESS OF PALIVIZUMAB FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN MODERATE-TO-LATE PRETERM INFANTS USING THE INTERNATIONAL RISK SCORING TOOL (IRST)	Barry	Rodgers-Gray
148	ARNI0155	Description and assessment of the unusual and unseasonal increase in RSV activity in Japan, 2021	Miyako	Otsuka

POSTER BOARD NO.	ABSTRACT	TITLE	Presenter/Author	
150	ARNI0255	Genomic surveillance strategy for Respiratory Syncytial Virus (RSV) in Brazil	Leticia	Scalioni
151	ARNI0090	RSV A-based Ad26/preF protein vaccine induces broadly neutralizing antibodies in nonclinical models and humans, that are protective against both RSV A and RSV B subtypes	Leslie	Van der Fits
152	ARNI0082	Ad26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challenge	Leslie	Van der Fits
153	ARNI0118	A two-component VLP vaccine platform for the development of a bivalent vaccine against RSV and hMPV	Andrew	Feldhaus
155	ARNI0211	Heterologous Prime-Boost Immunization Increases Cross-Reactive and Neutralizing Antibodies against Respiratory Syncytial Virus	Christopher	Anderson
156	ARNI0185	Identification of a good prognostic group (Positive-z-score-weighted Anorectic RSV-associated-SARI Infants, PARI) among infants hospitalized with RSV Severe Acute Respiratory Infection (SARI) during their first year of life in the 2013-2020 birth cohort of a large tertiary care center in Lyon, France	Come	Horvat
157	ARNI0220	Circulation of Respiratory Syncytial Virus in Nashville, Tennessee Before and During the COVID-19 Pandemic	Justin	Amarin
158	ARNI0262	Strategic Advocacy to support equitable access to vaccine-like RSV mAbs	Alexandra	Bhatti
159	ARNI0097	Molecular surveillance for respiratory viruses and genotyping of hRSV from a longitudinal prospective surveillance study of children under 2 in Melghat, India.	Varsha	Potdar
163	ARNI0049	Structural proteins of SARS-CoV-2 and their mutations to form basis of efficacy and longevity of vaccines	Ambreen	Khan
164	ARNI0108	The burden of respiratory syncytial virus on healthcare systems in Europe: results from a cross-sectional survey	Susanna	Esposito
165	ARNI0228	A characterisation of epithelium-leukocyte crosstalk induced by RSV infected airway epithelial cells from healthy and wheezing children	Lena	Glaser
167	ARNI0018	Estimating the Burden of Adult Hospitalized RSV Infection Including Special Populations	Balasubramani	G.K.
168	ARNI0159	Acute respiratory infections among individuals seeking outpatient care in the states of Washington and Michigan by pregnancy status, 2011-2016	Collrane	Frivold
170	ARNI0149	Severity of RSV infections in hospitalized children under 2 years of age: Portuguese experience from the first year of national surveillance	Ana Paula	Rodrigues
172	ARNI0158	Incidence and impact of respiratory syncytial virus-associated wheezing in early life: a birth cohort study in a low-income urban community in Dhaka, Bangladesh	Md. Zakiul	Hassan
173	ARNI0179	Respiratory Syncytial Virus Associated Clusters of Severe Acute Respiratory Infections Identified Through Hospital-based Surveillance in Bangladesh, 2009-2022	Md Ariful	Islam
174	ARNI0160	Respiratory Syncytial Virus-associated Deaths among Under-five Children before and during COVID-19 Pandemic in Bangladesh	Fahmida	Chowdhury
176	ARNI0066	Streptococcus pneumoniae Nasal Carriage Patterns with and without Common Respiratory Virus Infections in Seattle, WA, USA	Julia C.	Bennett
178	ARNI0130	Seasonal and inter-seasonal RSV activity in the WHO European Region between weeks 40/2020 and 19/2022	Margaux	Mesle
180	ARNI0263	RSV G protein monoclonal antibodies targeting the CX3C motif improve the antiviral response and protect against RSV mucogenic disease	Harrison	Bergeron

POSTER BOARD NO.	ABSTRACT	TITLE	Presenter/Author	
181	ARNI0214	IGF1R and PKCzeta activation mediate plasma membrane remodelling during RSV Entry	Quinten	Kieser
182	ARNI0156	RSV Epidemiology and Strain Identification in a Longitudinal Southeast Michigan Cohort of Households with Children	Emily	Martin
183	ARNI0257	EPIDEMIOLOGICAL AND DYNAMIC ANALYSIS OF CIRCULATION OF HUMAN RESPIRATORY SYNCYTIAL VIRUS STRAINS ISOLATED IN THE STATES OF ACRE AND PARÁIBA, BRAZIL, FROM JANUARY 2018 TO JUNE 2020	Jessylene	Ferreira
184	ARNI0219	CIRCULATION PATTERN OF HUMAN RESPIRATORY SYNCYTIAL VIRUS IN THE NORTH AND NORTHEAST REGIONS OF BRAZIL: EPIDEMIOLOGICAL AND EVOLUTIONARY ANALYSIS.	Jessylene	Ferreira
187	ARNI0058	Asthma dampens the human bronchial epithelial cell immune response to RSV infection	Richard	Hegele
188	ARNI0011	New antivirals against human parainfluenza virus	Iebe	Rossey
189	ARNI0031	An unexpected encounter: RSV-NS1 interacts with a subunit of the mediator complex	Tessa	Van Royen
190	ARNI0275	THE EFFICIENCY OF P27 PEPTIDE CLEAVAGE DURING IN VITRO RSV INFECTION IS CELL LINE AND RSV SUBTYPE DEPENDENT	Wanderson	Rezende
192	ARNI0081	Comparing the association between RSV and non-RSV lower respiratory tract illness and subsequent wheezing illness using causal models: a secondary analysis of a systematic review and meta-analysis	Samar	Mehta
194	ARNI0269	Pediatric burden and seasonality of Human Metapneumovirus over five years in Managua, Nicaragua.	Kathryn	Hacker
195	ARNI0181	Estimating RSV seasonality from pandemic disruptions: a modelling study	Fabienne	Krauer
196	ARNI0153	Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in Respiratory syncytial Virus (RSV) Infected Infants	Mary	Caserta
198	ARNI0034	Dose adjustment of riletamovir in combination with CYP3A4 inhibitors based on PBPK modeling and clinical data	Tristan	Baguet
199	ARNI0079	Clinician Evaluations Show Increased Acute Respiratory Tract Infection Severity in Older Adults and Adults With Core Risk Factors - Data From the Global Hospitalized Acute Respiratory Tract Infection (HARTI) Study	Ann R.	Falsey